Antenatal Corticosteroids: Administration Guidelines and Contraindications
Administer a single course of betamethasone (two 12 mg intramuscular doses 24 hours apart) to pregnant women between 34 0/7 and 36 6/7 weeks gestation with singleton pregnancies who are at high risk of delivering within the next 7 days. 1
When to Administer Antenatal Corticosteroids
Primary Indication (GRADE 1A - Strongest Evidence)
For gestational ages 34 0/7 to 36 6/7 weeks:
- Singleton pregnancy
- High probability of delivery within 7 days AND before 37 weeks
- Specific high-risk criteria include:
- Preterm labor with cervical dilation ≥3 cm OR ≥75% effacement
- Spontaneous rupture of membranes
- Planned delivery for maternal/fetal indications (preeclampsia, fetal growth restriction, oligohydramnios) within 24 hours to 7 days 1
For gestational ages 24 0/7 to 33 6/7 weeks:
- Same criteria apply with even stronger evidence for benefit
- Reduces respiratory distress syndrome, intraventricular hemorrhage, necrotizing enterocolitis, and neonatal death 1, 2
Evidence Supporting This Approach
The ALPS trial demonstrated that betamethasone administration in the late preterm period reduced the need for respiratory support (11.6% vs 14.4%; RR 0.80) and severe respiratory morbidity (8.1% vs 12.1%; RR 0.67) 1. These benefits translate directly to reduced neonatal morbidity and improved quality of life for affected infants.
How to Administer
Dosing Regimen (GRADE 1A)
Betamethasone: 12 mg intramuscularly, two doses 24 hours apart 1
Alternative acceptable regimen:
- Dexamethasone: 6 mg intramuscularly every 12 hours for 4 doses, OR 12 mg intramuscularly twice 24 hours apart 3
Timing Considerations
- Optimal benefit: Delivery occurring 24 hours to 7 days after first dose
- Still beneficial: Even if delivery expected in <12 hours, administer at least one dose 1
- Do not delay: If imminent delivery, give first dose immediately rather than waiting for "perfect" timing
Absolute Contraindications (GRADE 1C)
Pregestational Diabetes Mellitus
Do not administer late preterm corticosteroids (34-36 weeks) to women with pregestational diabetes due to significantly increased risk of neonatal hypoglycemia 1. This is the only clearly established contraindication in the guidelines.
Important caveat: Gestational diabetes is NOT a contraindication—corticosteroids can still be used with appropriate glucose monitoring 3, 4.
When NOT to Administer (GRADE 1B)
Low Likelihood of Preterm Delivery
Do not give corticosteroids to women with low probability of delivery before 37 weeks 1. This represents overuse and exposes the fetus to unnecessary risks without benefit.
The evidence shows that 25.9% of women who received antenatal steroids before 34 weeks ultimately delivered at term 5, highlighting the challenge of accurate prediction and the importance of restricting use to truly high-risk patients.
After 37 Weeks Gestation
Do not administer for scheduled cesarean delivery at term—no demonstrated benefit and long-term safety unknown 3
Special Populations
Consider Use (GRADE 2C - Weaker Evidence)
- Multiple gestations reduced to singleton at or after 14 0/7 weeks
- Fetal anomalies
- Expected delivery in <12 hours 1
Twin/Multiple Gestations
- Same dosing as singletons
- Reserve for pregnancies at genuinely high risk of delivery within 7 days 3
Periviable Period (22-23 weeks)
- Consider if active neonatal resuscitation planned
- Discuss with family regarding goals of care
- Evidence shows survival benefit but unclear long-term neurodevelopmental impact 3
Critical Pitfalls to Avoid
Overuse in low-risk patients: Nearly 26% of women receiving steroids before 34 weeks deliver at term 5—ensure genuine high risk before administering
Repeat courses: Do NOT give regularly scheduled repeat courses or multiple courses (>2 total). A single rescue course may be considered if >14 days since prior course, <34 weeks gestation, and delivery likely within 7 days 6, 2
Ignoring diabetes status: Always screen for pregestational diabetes before late preterm steroid administration 1
Inadequate counseling: Patients must understand that long-term neurodevelopmental risks remain uncertain, particularly for late preterm administration 1
Misinterpreting fetal monitoring: Corticosteroids temporarily alter fetal heart rate patterns and movements—recognize this to avoid unnecessary interventions 4
Risk-Benefit Balance
Benefits clearly outweigh risks when used appropriately: The ALPS trial showed significant reductions in respiratory morbidity with number needed to treat of approximately 35 for any respiratory support and 25 for severe respiratory morbidity 1. However, the treatment does increase neonatal hypoglycemia risk (though typically mild and self-limited, resolving in <24 hours in 93% of cases) 1.
Long-term concerns remain unresolved: Animal studies suggest potential effects on fetal brain development, particularly after 34 weeks when rapid brain growth occurs 1. This uncertainty reinforces the importance of restricting use to patients with genuine high risk of imminent preterm delivery.